Reference intervals for circulating angiogenic cytokines

Clinical Chemistry and Laboratory Medicine

Volumn 46, Issue 4, 2008, Pages 545-550

  Kong, Sun Young ^a,b   Lee, Hye Lin ^a   Eom, Hyeon Seok ^a,c   Park, Weon Seo ^a,c   Yun, Tak ^c   Kim, Hyun Ju ^c   Nam, Byung Ho ^a   Seong, Moon Woo ^b   Lee, Do Hoon ^b  

^a National Cancer Center   (South Korea)

^b National Cancer Center   (South Korea)

^c National Cancer Center   (South Korea)

Author keywords

Angiogenic cytokine; Reference interval

Indexed keywords

ANGIOGENIC PROTEIN; BASIC FIBROBLAST GROWTH FACTOR; INTERLEUKIN 6; SCATTER FACTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA POLYMORPHISM; FEMALE; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; URINALYSIS;

ADULT; AGED; BLOOD CHEMICAL ANALYSIS; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; FIBROBLAST GROWTH FACTOR 2; HEPATOCYTE GROWTH FACTOR; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; POLYMORPHISM, GENETIC; REFERENCE VALUES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 44949211532     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2008.092     Document Type: Article

References (26)

1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
2. McCarthy M. Antiangiogenesis drug promising for metastatic colorectal cancer. Lancet 2003;361:1959.
3. Herbst RS, Onn A, Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 2005;23:3243-56.
4. Jacobsen J, Rasmuson T, Grankvist K, Ljungberg B. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000;163:343-7.
5. Yao JC, Wang L, Wei D, Gong W, Hassan M, Wu TT, et al. Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res 2004;10:4109-17.
6. Khorana AA, Ryan CK, Cox C, Eberly S, Sahasrabudhe DM. Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with stage II and stage III colon carcinoma: a role for the host response in prognosis. Cancer 2003;97:960-8.
7. Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 2006;51:143-58.
8. Martin K, Viera K, Petr C, Marie N, Eva T. Simultaneous analysis of cytokines and co-stimulatory molecules concentrations by ELISA technique and of probabilities of measurable concentrations of interleukins IL-2, IL-4, IL-5, IL-6, CXCL8 (IL-8), IL-10, IL-13 occurring in plasma of healthy blood donors. Mediat Inflamm 2006;2006: article id 65237.
9. Berrahmoune H, Lamont JV, Herbeth B, FitzGerald PS, Visvikis-Siest S. Biological determinants of and reference values for plasma interleukin-8, monocyte chemoattractant protein-1, epidermal growth factor, and vascular endothelial growth factor: results from the STANISLAS cohort. Clin Chem 2006;52:504-10.
10. Clinical and Laboratory Standards Institute. How to define and determine reference intervals in the clinical laboratory; approved guideline (2nd ed). CLSI document C28-A2. Wayne, PA: Clinical and Laboratory Standards Institute, 2000.
11. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-89.
12. Stephens M, Scheet P. Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet 2005;76:449-62.
13. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-5.
14. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24.
15. Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 2007;13:2643-50.
16. Loupakis F, Falcone A, Masi G, Fioravanti A, Kerbel RS, Del Tacca M, et al. Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity. J Clin Oncol 2007;25:1816-8.
17. Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Sivridis E. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 2004;46:293-8.
18. Shahbazi M, Fryer AA, Pravica V, Brogan IJ, Ramsay HM, Hutchinson IV, et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 2002;13:260-4.
19. Breunis WB, Biezeveld MH, Geissler J, Ottenkamp J, Kuipers IM, Lam J, et al. Vascular endothelial growth factor gene haplotypes in Kawasaki disease. Arthritis Rheum 2006;54:1588-94.
20. Schulz S, Kohler K, Schagdarsurengin U, Greiser P, Birkenmeier G, Muller-Werdan U, et al. The human FGF2 level is influenced by genetic predisposition. Int J Cardiol 2005;101:265-71.
21. Boiardi L, Casali B, Farnetti E, Pipitone N, Nicoli D, Cantini F, et al. Relationship between interleukin 6 promoter polymorphism at position -174, IL-6 serum levels, and the risk of relapse/recurrence in polymyalgia rheumatica. J Rheum 2006;33:703-8.
22. Kitamura A, Hasegawa G, Obayashi H, Kamiuchi K, Ishii M, Yano M, et al. Interleukin-6 polymorphism (-634C/G) in the promotor region and the progression of diabetic nephropathy in type 2 diabetes. Diabet Med 2002;19:1000-5.
23. Sakon M, Kita Y, Takeda Y, Higaki N, Ohzato H, Umeshita K, et al. Measurement of hepatocyte growth factor in serum and plasma. Int J Clin Lab Res 1999;29:110-3.
24. Werther K, Christensen IJ, Nielsen HJ. Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Br J Cancer 2002;86:417-23.
25. Webb NJ, Bottomley MJ, Watson CJ, Brenchley PE. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci (Lond) 1998;94:395-404.
26. George ML, Eccles SA, Tutton MG, Abulafi AM, Swift RI. Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin Cancer Res 2000;6:3147-52.